To Build the World’s leading Pharma Solutions Platform
Porton has a highly experienced regulatory affairs team which provides CMC services at all research stages of Investigational New Drug application (IND/CTA) and its clinical trial phases (P1, P2, P3), New Drug Applications (NDA/MAA), Abbreviated New Drug Application (ANDA), and post-approval regulatory services including product change, annual report and re-registration service. We are strongly acquainted with regulatory expectations of all major global agencies such as USFDA, EMA, PMDA, NMPA and TGA.
We can provide comprehensive API life cycle service management ranging from late-phase clinical development to filing, post-approval commercial and end of exclusivity. Taking a proactive approach, our regulatory affairs group can provide gap analysis where required and relevant CMC data of Modules 2 and 3 of in CTD format and other formats required.
With extensive API CMC filing experience throughout the world and as a Holder of multiple DMFs, Porton has submitted filings for over 30 products filed with all major regulatory bodies such as USFDA, EU EDQM, WHO, Japan PMDA, China NMPA, Canada TPD covering IND, NDA and ANDA submissions.
Porton has the manufacturing facilities, which has successfully passed the GMP site inspections conducted by US FDA, EU EMA, Japan PMDA and China NMPA.